Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Am J Ophthalmol ; 244: 11-18, 2022 12.
Artigo em Inglês | MEDLINE | ID: mdl-35948088

RESUMO

PURPOSE: To investigate a causal relationship between Vitamin D levels and non-infectious uveitis and scleritis using Mendelian randomization (MR) techniques. DESIGN: Two-sample Mendelian randomization case-control study. METHODS: The study setting was a biobank of an academic, integrated health care system. The patient population comprised 375 case patients with a non-infectious uveitis and/or scleritis diagnosis and no diagnosis of infectious, trauma-related, or drug-induced uveitis/scleritis. In addition, there were 4167 controls with no uveitis or scleritis diagnosis. Causal effect estimates of low 25-hydroxy Vitamin D (25OHD) on uveitis/scleritis risk were calculated. RESULTS: We found an association of genetically decreased 25OHD with uveitis/scleritis risk (odds ratio [OR] = 2.16, 95% CI = 1.01-4.64, P = .049, per SD decrease in log25OHD). In a first sensitivity MR analysis excluding the genetic variants that are unlikely to have a role in biologically active 25OHD, effect estimates were consistent with those from the primary analysis (OR = 2.38, 95% CI =1.06-5.36, P = 0.035, per SD of log25OHD). Furthermore, in a second sensitivity analysis using only the 6 variants within the CYP2R1 locus (which encodes 25OHD hydroxylase, the liver enzyme responsible for converting Vitamin D to 25OHD), genetically decreased 25OHD was strongly associated with increased uveitis/scleritis risk (OR = 6.42, 95% CI = 3.19-12.89, P = 1.7 × 10-7, per SD of log25OHD). CONCLUSIONS: Our findings suggest a causal relationship between low Vitamin D levels and higher risk of non-infectious uveitis and scleritis. Vitamin D supplementation may be a low-cost, low-risk intervention to mitigate non-infectious uveitis and scleritis risk, and should be explored in a prospective trial.


Assuntos
Esclerite , Uveíte , Humanos , Análise da Randomização Mendeliana/métodos , Esclerite/diagnóstico , Esclerite/tratamento farmacológico , Esclerite/genética , Estudos de Casos e Controles , Estudos Prospectivos , Polimorfismo de Nucleotídeo Único , Fatores de Risco , Vitamina D , Vitaminas , Uveíte/diagnóstico , Uveíte/genética , Estudo de Associação Genômica Ampla
2.
Semin Ophthalmol ; 32(1): 75-81, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-27805464

RESUMO

Inflammatory conditions such as autoimmune uveitis often occur in women of childbearing age. During pregnancy, women may experience exacerbations of their disease in the first trimester. In the later stages of pregnancy, however, the uveitis tends to remain less active. The management of uveitis during pregnancy is a challenging task, forcing the physician to re-evaluate the patient's current therapy and offer alternative options that pose the least risk to the patient and fetus. This article will review treatments widely used for uveitis, including corticosteroid therapy, anti-metabolites, calcineurin inhibitors, and biologic therapy. It will evaluate the use of these medications in pregnancy and the postpartum state.


Assuntos
Complicações na Gravidez , Uveíte/tratamento farmacológico , Uveíte/fisiopatologia , Adulto , Antimetabólitos/uso terapêutico , Doenças Autoimunes/tratamento farmacológico , Doenças Autoimunes/fisiopatologia , Terapia Biológica , Inibidores de Calcineurina/uso terapêutico , Feminino , Glucocorticoides/uso terapêutico , Humanos , Período Pós-Parto , Gravidez
4.
Ophthalmology ; 110(4): 786-9, 2003 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-12689903

RESUMO

PURPOSE: To evaluate the efficacy and safety of daclizumab therapy for patients with various ophthalmologic inflammatory disorders (all having previously failed standard treatment methods). DESIGN: Retrospective, nonrandomized case series. PARTICIPANTS: Fourteen patients. METHODS: Fourteen patients were treated with daclizumab after previously failing standard treatment methods. MAIN OUTCOME MEASURES: Inflammation and visual acuity. RESULTS: Twelve of 27 (44%) eyes and 5 of 14 (36%) patients had improvement in visual acuity; 9 of 27 (33%) eyes and 5 of 14 (36%) patients had no change in visual acuity; and 6 of 27 (22%) eyes and 4 of 14 (27%) patients had continued visual loss. Based on degree of inflammation, 16 of 27 eyes (59%) had improvement, 3 of 27 (11%) eyes had no change, and 8 of 27 (30%) eyes worsened. CONCLUSIONS: Daclizumab is safe and, at least in some patients, appears to be an effective medication in the treatment of ocular inflammatory disorders.


Assuntos
Anticorpos Monoclonais/uso terapêutico , Conjuntivite/tratamento farmacológico , Imunoglobulina G/uso terapêutico , Imunossupressores/uso terapêutico , Penfigoide Mucomembranoso Benigno/tratamento farmacológico , Esclerite/tratamento farmacológico , Uveíte/tratamento farmacológico , Adolescente , Adulto , Idoso , Anticorpos Monoclonais Humanizados , Criança , Daclizumabe , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento , Acuidade Visual
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA